The Avandia/Actos battle has been making headlines since August 19 (BMJ.com) when a Canadian researcher suggested the oral diabetes treatment Actos is safer than Avandia. (Coincidentally, Takeda Canada announced a few days later that it reacquired the Canadian marketing rights for its Actos from Eli Lilly’s Canadian company. The drugmaker licensed the rights to Lilly under a worldwide agreement in 1999—financial arrangements were not disclosed.)
The similarities: Both Avandia and Actos belong to a class of drugs called thiazolidinediones, which are used widely to lower blood sugar in people with type 2 diabetes. In addition to an increased risk for heart failure, both drugs can also cause side effects that include weight gain and fluid retention. Both medications carry a U.S. Food and Drug Administration warning and both meds run the same risk of heart attack.
The discrepancies: Researchers found that patients taking Avandia were at greater risk of